West Pharmaceutical Services, Inc.
WST
$263.51
-$15.59-5.59%
NYSE
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | 9.17% | 0.37% | 2.30% | -0.07% | -6.86% |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 9.17% | 0.37% | 2.30% | -0.07% | -6.86% |
Cost of Revenue | 4.34% | 0.19% | 4.69% | 5.03% | 2.30% |
Gross Profit | 19.09% | 0.74% | -1.62% | -8.19% | -21.31% |
SG&A Expenses | 13.86% | -0.12% | -8.16% | -7.98% | -6.11% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | 0.00% | -100.00% | 250.00% | -- |
Total Operating Expenses | 5.92% | -0.09% | 2.30% | 2.85% | 1.04% |
Operating Income | 23.55% | 2.47% | 2.26% | -9.06% | -30.79% |
Income Before Tax | 21.62% | -13.52% | -2.68% | -11.69% | -29.86% |
Income Tax Expenses | 37.90% | 46.95% | 6.67% | 10.20% | -37.07% |
Earnings from Continuing Operations | 18.42% | -22.12% | -5.04% | -15.69% | -28.24% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 18.42% | -22.12% | -5.04% | -15.69% | -28.24% |
EBIT | 23.55% | 2.47% | 2.26% | -9.06% | -30.79% |
EBITDA | 19.60% | 4.65% | 4.22% | -5.53% | -23.87% |
EPS Basic | 19.73% | -21.04% | -3.21% | -13.95% | -26.96% |
Normalized Basic EPS | 25.25% | 2.21% | 4.40% | -9.37% | -29.51% |
EPS Diluted | 20.53% | -20.65% | -2.10% | -13.55% | -26.70% |
Normalized Diluted EPS | 25.92% | 2.62% | 4.80% | -8.90% | -29.14% |
Average Basic Shares Outstanding | -1.10% | -1.36% | -1.89% | -2.02% | -1.75% |
Average Diluted Shares Outstanding | -1.63% | -1.75% | -2.27% | -2.52% | -2.25% |
Dividend Per Share | 5.00% | 5.00% | 5.00% | 5.26% | 5.26% |
Payout Ratio | -0.13% | 0.33% | 0.09% | 0.23% | 0.44% |